Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review.
Approximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2), providing an actionable target for many different therapies. In the metastatic setting, prognosis has improved greatly with the use of anti-HER2 drugs such as trastuzumab, pertuzumab, and trastuzumab-emt...
| Publicado en: | Current Oncology Vol. 29; no. 4; pp. 2539 - 2550 |
|---|---|
| Autores principales: | , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Apr2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=156533358&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 156533358 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Apr2022 vid: 29 iid: 4 pid: 97109 pub: MDPI artinfo: ui: 156533358 10.3390/curroncol29040208 156533358 ppf: 2539 ppct: 11 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review. aug: au: Lebert, Julie Lilly, Evan J. affil: Department of Oncology, Bluewater Health, Sarnia, ON N7T 6S3, Canada sug: ab: Approximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2), providing an actionable target for many different therapies. In the metastatic setting, prognosis has improved greatly with the use of anti-HER2 drugs such as trastuzumab, pertuzumab, and trastuzumab-emtansine. In the third line setting and beyond, several emerging treatments have shown benefits, including novel small molecule targeted agents and antibody-drug conjugates. Systemic treatment of brain metastases in HER2-positive patients and the role of endocrine-based treatment for patients with hormone receptor (HR) positive disease remain areas of research interest. This article will review the current approach to systemic management of metastatic HER2-positive breast cancer in Canada, and present novel treatments that may be available in the near future. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|